Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93170 citas

 
 
 1 a 12 de 12 
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, for the GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance. The GAUSS-3 randomized clinical trial. JAMA 2016;315:1580-90. [Ref.ID 100239]
2.Tiene citas relacionadas Cita con resumen
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Med M, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. [Ref.ID 99056]
3. Cita con resumen
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Scott R, Wasserman SM, Stein EA, for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50. [Ref.ID 98743]
4. Cita con resumen
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Wasserman SM, Gaudet D, for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331-40. [Ref.ID 98742]
5.Tiene citas relacionadas Cita con resumen
Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardiff CM, Rudd JHF, Farkouh ME, Tawakol A, for the dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59. [Ref.ID 91765]
6. Cita con resumen
Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DCG, Kastelein JJP, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA, for the CAPTIVATE Investigators. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia. The CAPTIVATE randomized trial. JAMA 2009;301:1131-9. [Ref.ID 85496]
7.Tiene citas relacionadas Cita con resumen
Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFH, Visseren FLJ, Sijbrands EJG, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-3. [Ref.ID 82523]
8. Cita con resumen
Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless J P D, Stein EA. Risk of myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64. [Ref.ID 65456]
9.Tiene citas relacionadas
Stein EA, Illingworth DR, Kwiterovich PO, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn J, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. A randomized controlled trial. JAMA 1999;281:131-44. [Ref.ID 42512]
10.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendörfer A, Stein EA, Kruyer W, Gotto AM, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22. [Ref.ID 38545]
11.
Corsini A, Stein EA. Cerivastatin: viewpoints. Drugs 1998;55:421-2. [Ref.ID 37247]
12.
Hunninghake DB, Stein EA, Dujovne CA, Harris WS, Feldman EB, Miller VT, Tobert JA, Laskarzewski PM, Quiter E, Held J, Taylor AM, Hopper S, Leonard SB, Brewer BK. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993;328:1213-9. [Ref.ID 19235]
Seleccionar todas
 
 1 a 12 de 12